1. Home
  2. NERV vs MSLE Comparison

NERV vs MSLE Comparison

Compare NERV & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

N/A

Current Price

$2.33

Market Cap

166.4M

Sector

Health Care

ML Signal

N/A

Logo Satellos Bioscience Inc. Common Stock

MSLE

Satellos Bioscience Inc. Common Stock

N/A

Current Price

$6.93

Market Cap

144.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NERV
MSLE
Founded
2007
2018
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
166.4M
144.6M
IPO Year
2014
2007

Fundamental Metrics

Financial Performance
Metric
NERV
MSLE
Price
$2.33
$6.93
Analyst Decision
Buy
Strong Buy
Analyst Count
3
9
Target Price
$10.33
★ $24.17
AVG Volume (30 Days)
★ 179.3K
43.2K
Earning Date
11-06-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $41,175,600.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.96
$5.44
52 Week High
$8.80
$13.39

Technical Indicators

Market Signals
Indicator
NERV
MSLE
Relative Strength Index (RSI) 39.95 43.96
Support Level $1.96 $6.50
Resistance Level $2.65 $7.19
Average True Range (ATR) 0.24 0.54
MACD 0.06 0.09
Stochastic Oscillator 42.50 36.22

Price Performance

Historical Comparison
NERV
MSLE

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc a clinical-stage biopharmaceutical company focused on the development and commercialization of certain proprietary product candidates to treat patients suffering from central nervous system (CNS) diseases. Its product candidate, Roluperidone, is in development for the treatment of negative symptoms in patients diagnosed with schizophrenia. Its Clinical-Stage Programs include Roluperidone and Seltorexant. The company's operations are organized into one operating and reportable segment focused on the development and commercialization of proprietary product candidates to treat patients suffering from CNS diseases.

About MSLE Satellos Bioscience Inc. Common Stock

Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.

Share on Social Networks: